| Cash Flow | 2026-06-30 |
|---|---|
| Net (loss) income | -17,791,065 |
| Depreciation expense | 64,600 |
| Amortization expense | 1,165,154 |
| Amortization of debt discount | 0 |
| Amortization of right-of-use asset | 106,716 |
| Stock-based compensation expense | 3,914,096 |
| Fair value adjustment to contingent consideration | 1,412,000 |
| Gain on extinguishment of debt | 815,250 |
| Deferred tax benefit | 0 |
| Accounts receivable | -3,253,111 |
| Inventory | 1,834,615 |
| Prepaid expenses and other assets | 364,256 |
| Accounts payable and accrued expenses | 4,911,963 |
| License fees payable | -295,200 |
| Income tax payable | -31,512 |
| Accrued interest | 99,083 |
| Other current and long-term liabilities | -158,802 |
| Net cash (used in) provided by operating activities | -6,363,977 |
| Purchases of property and equipment and construction-in- process | 57,925 |
| Cash paid in business combination | 15,018,371 |
| Net cash used in investing activities | -15,076,296 |
| Repayments on notes payable | 3,500,000 |
| Proceeds from issuance of common stock | 2,500,000 |
| Cash paid to third parties for issuance of common stock | 146,253 |
| Issuance of common stock for warrant exercise | 0 |
| Net cash used in financing activities | -1,146,253 |
| Cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), excluding exchange rate effect, including discontinued operation, total | -22,586,526 |
| Balance, beginning of period | 29,549,018 |
| Balance, end of period | 6,962,492 |
BioStem Technologies, Inc. (BSEM)
BioStem Technologies, Inc. (BSEM)